In Endo Pharmaceuticals Inc., v. Teva Pharmaceuticals USA, Inc., [ 2017-1240, 2017-1455, 2017-1887](March 28, 2019), the Federal Circuit reversed the district court’s determination that the claims of U.S. Patent No. 8,808,737 ineligible under 35 U.S.C. § 101. The ’737 patent, … Continue reading Precedent Leaves No Room for Different Outcome; Method of Treating Specific Disease is Patent Eligible